Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN60,9560,98-0,67
Msft-1,00
Nokia3,75053,7995-0,41
IBM0,38
Mercedes-Benz Group AG57,5357,550,77
PFE-0,27
19.09.2024 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 18.09.2024
Aurinia Pharma (NASDAQ Cons)
Závěr k 18.9.2024 Změna (%) Změna (USD) Objem obchodů (ks)
7,08 -0,84 -0,06 929 388
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 19.09.2024
Popis společnosti
Obecné informace
Název společnostiAurinia Pharmaceuticals Inc
TickerAUPH
Kmenové akcie:Ordinary Shares
RICAUPH.O
ISIN-
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky30.06.2024
Počet zaměstnanců k 31.12.2023 300
Akcie v oběhu k 31.07.2024 142 990 974
MěnaUSD
Kontaktní informace
Ulice#140, 14315 - 118 AVENUE
MěstoVICTORIA
PSČT5L 4S6
ZeměCanada
Kontatní osoba 
Funkce kontaktní osoby 
Telefon12 507 442 487
Fax16043694115

Business Summary: Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is primarily engaged in the development of its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The Company contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for the development and commercialization of LUPKYNIS in the Otsuka Territories. It sells LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor and directly to its ex-U.S. partner, Otsuka.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Aurinia Pharmaceuticals Inc revenues increased 42% to $107.5M. Net loss decreased 73% to $10M. Revenues reflect Therapeutic Drug Division segment increase from $83M to $215M. Lower net loss reflects Therapeutic Drug Division segment loss decrease of 9% to $14.8M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.26 to -$0.07.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICS2007Research and Development in Biotechnology
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICCommercial Physical Research



  • Poslední aktualizace: 19.09.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorPeter Greenleaf5429.04.201929.04.2019
Chief Financial OfficerJoe Miller5027.04.202027.04.2020
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate SecretaryStephen Robertson4220.11.202020.11.2020
Executive Vice President, Operations and StrategyMatthew Donley55
Chief Commercial OfficerScott Habig6414.07.202214.07.2022